PFE
Pfizer Inc.
Stock$27.12
+$0.08 (+0.30%)
Current Price (API): $27.12About
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Price History (Last 30 Days)
Latest News & Updates
Despite setbacks including a failed GLP-1 drug candidate and a 50% stock decline...
Despite setbacks including a failed GLP-1 drug candidate and a 50% stock decline from 2021 highs, Pfizer demonstrates resilience by quickly acquiring a promising GLP-1 competitor and showing progress in early 2026. The article argues that long-term investors shouldn't count out the pharmaceutical giant, which maintains a $150B market cap, a 6.2% dividend yield, and a track record of navigating industry challenges.
Viking Therapeutics' VK2735, a GLP-1 weight loss drug candidate, could become a...
Viking Therapeutics' VK2735, a GLP-1 weight loss drug candidate, could become a major player in the $100 billion weight loss market. Upcoming phase 3 clinical trial results could trigger a threefold stock surge if positive, making Viking an acquisition target. However, the investment is highly binary and risky, with significant downside if trials disappoint.
While Eli Lilly dominates the GLP-1 drug market with impressive sales growth fro...
While Eli Lilly dominates the GLP-1 drug market with impressive sales growth from Mounjaro and Zepbound, the stock trades at a lofty 40x P/E ratio—well above pharma averages. The article warns that investors have priced in perfection, ignoring inevitable patent expirations and increasing competition from rivals developing alternative GLP-1 formulations. Despite strong current performance, the valuation makes Eli Lilly an unattractive long-term investment at current prices.
Pomerantz LLP is investigating potential securities fraud claims against Valneva...
Pomerantz LLP is investigating potential securities fraud claims against Valneva SE and partner Pfizer following the failure of their Phase 3 Lyme disease vaccine candidate (LB6V) to meet its primary endpoint. The announcement triggered a sharp 37.11% decline in Valneva's ADR price on March 23, 2026.
Serina Therapeutics, a clinical-stage biotech company, announced that CEO Steve...
Serina Therapeutics, a clinical-stage biotech company, announced that CEO Steve Ledger will present at the 38th Annual Roth Conference on March 24, 2026. The company is developing its proprietary POZ Platform™ technology for drug optimization, with a focus on treating neurological diseases. Serina has a pipeline including SER-252 (POZ-apomorphine) for Parkinson's disease and has secured partnerships including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery applications.
Valneva and Pfizer's Phase 3 VALOR trial for their Lyme disease vaccine failed t...
Valneva and Pfizer's Phase 3 VALOR trial for their Lyme disease vaccine failed to meet its primary endpoint due to fewer cases being accrued than expected. However, secondary analyses showed clinically meaningful efficacy of 73-75%, and Pfizer plans to proceed with regulatory submissions. Valneva shares fell 35.27% on the news, trading significantly below key moving averages.
The article recommends two healthcare stocks for long-term investors with $500 t...
The article recommends two healthcare stocks for long-term investors with $500 to invest. Pfizer, trading at 9x forward earnings, has faced revenue declines post-COVID but is positioning for growth through oncology acquisitions and entry into the obesity drug market. UnitedHealth Group, trading at 15x forward earnings, struggled with underestimated healthcare costs but has implemented cost-cutting measures and AI optimization to recover.
Anaveon, a late-stage preclinical biotech company focused on immune system repro...
Anaveon, a late-stage preclinical biotech company focused on immune system reprogramming, announced the appointment of Thaminda Ramanayake as CEO. Ramanayake brings over 20 years of biopharmaceutical leadership experience, including roles at CureVac, Sanofi, BioMarin, and Amgen. He will lead Anaveon's advancement of its immunology pipeline toward clinical development, with ANV200 as the lead asset for T cell depletion in autoimmune and inflammatory diseases.
The article recommends three pharmaceutical stocks as attractive long-term holdi...
The article recommends three pharmaceutical stocks as attractive long-term holdings: Eli Lilly, which dominates the growing chronic weight management market with its blockbuster drug tirzepatide; Vertex Pharmaceuticals, which maintains a monopoly in cystic fibrosis treatments while expanding into other therapeutic areas; and Pfizer, which despite recent underperformance, offers undervalued shares, a strong pipeline, and an attractive 6.3% dividend yield.
Healthcare stocks are experiencing a pullback amid Middle East geopolitical tens...
Healthcare stocks are experiencing a pullback amid Middle East geopolitical tensions, but the sector remains resilient. The article reviews five healthcare dividend-paying stocks and funds offering yields between 6% and 14.1%, analyzing their fundamentals and risks including patent cliffs, real estate headwinds, and distribution sustainability.
